Currently identified T-cell antigens for immunotherapeutic targeting under preclinical or clinical study
| Target . | T-ALL/T-LL frequency . | Normal tissue expression . | Selected references . |
|---|---|---|---|
| CD1a | 80%/67% | Cortical thymocytes, immature dendritic cells, Langerhans cells | 11 |
| CD3 | 33%/46% | Thymocytes, mature T cells, NK cells | 40 |
| CD4 | 82%/72% | T-helper cells, thymocytes, granulocytes, monocytes, dendritic cells, Langerhans cells | 23 |
| CD5 | 88%/95% | Mature T cells, thymocytes, B cells | 17 |
| CD7 | 98%/97% | Mature T cells, thymocytes, NK cells | 20 |
| CD38 | 100%/100% | Plasma cells, hematopoietic progenitor cells, T cells, NK cells, B cells | 12 |
| CD123 | 43%/— | Plasmacytic dendritic cells, eosinophils | 41 |
| TRBC1 | 30%/— | T cells | 24 |
| Target . | T-ALL/T-LL frequency . | Normal tissue expression . | Selected references . |
|---|---|---|---|
| CD1a | 80%/67% | Cortical thymocytes, immature dendritic cells, Langerhans cells | 11 |
| CD3 | 33%/46% | Thymocytes, mature T cells, NK cells | 40 |
| CD4 | 82%/72% | T-helper cells, thymocytes, granulocytes, monocytes, dendritic cells, Langerhans cells | 23 |
| CD5 | 88%/95% | Mature T cells, thymocytes, B cells | 17 |
| CD7 | 98%/97% | Mature T cells, thymocytes, NK cells | 20 |
| CD38 | 100%/100% | Plasma cells, hematopoietic progenitor cells, T cells, NK cells, B cells | 12 |
| CD123 | 43%/— | Plasmacytic dendritic cells, eosinophils | 41 |
| TRBC1 | 30%/— | T cells | 24 |
NK, natural killer; T-ALL, T-cell acute lymphoblastic leukemia; T-LL, T-cell lymphoblastic lymphoma.